Clinical trials: Kidney Cancer With PBRM1/BAP1/VHL/SETD2 Mutations
Clear Cell Kidney Cancer, Kidney Cancer
An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)
Kidney cancer belongs to a heterogeneous group of tumors and is the most common oncourological disease; up to 80% of cases are clear cell carcinoma.
- Conditions
- Clear Cell Kidney Cancer, Kidney Cancer, Kidney Cancer With PBRM1/BAP1/VHL/SETD2 Mutations
- Trial name
- NCT05941637
- Testing
- Axitinib 5 MG
- Sponsor
- Lynkcell Europe